Search results
277 Results for 'Donald E. Ingber'
- Technologies (20)
- Collaborations (2)
- Team (0)
- News (192)
- Events (17)
- Multimedia (46)
- Publications (0)
- Jobs (0)
Technologies 20
-
Sugar-to-Fiber Enzyme for Healthier Food
In collaboration with Kraft Heinz, our sugar-to-fiber product can convert sugar in food products into prebiotic fiber in the human gut, reducing the amount of sugar absorbed into the bloodstream without altering the amount of sugar in existing food product recipes. -
eRapid: Multiplexed Electrochemical Detection of Complex Diseases
StataDX licensed the eRapid portable electrochemical sensing technology to develop diagnostics for neurological, cardiovascular, and renal diseases with a first focus on building a point-of-care platform for difficult-to-detect neurological disorders. -
CircaVent: A Drug Discovery Platform for Mental Health Conditions
CircaVent is a novel drug discovery platform that combines predictive algorithms, high-throughput preclinical models, and human organoids to identify and test drugs that could treat mental health conditions like bipolar disorder. -
Origami-Inspired Radiant Cooling for Improved Thermal Health
Origami-inspired Radiant Cooling devices for a broad range of building interiors use microfluidic water-circuits and foldable designs that increase their surface area to achieve more effective cooling. -
OrbitSeq: A Collaborative Digital Hub for Life Sciences Data
OrbitSeq is a digital platform that empowers life sciences researchers to browse, upload, and analyze datasets, and easily collaborate with each other to bring science closer together and speed up the pace of discovery. -
Broad-Spectrum RNA Therapeutic for Treatment of COVID-19 and Influenza
Our novel dsRNAs stimulate the immune system to inhibit many respiratory infections, including SARS-CoV-2, related SARS viruses, and multiple influenza strains.
Collaborations 2
-
Kraft Heinz Partnership
The Kraft Heinz company approached the Wyss Institute for help to achieve its ambitious goal to make its food products healthier, resulting in a novel technology that is ripe for commercialization. -
Brain Targeting Program
Pre-competitive multi-partner industry collaboration that aims to identify novel transport targets and shuttle compounds to enable more effective delivery of drugs to the brain.
News 192
Events 17
-
Mar 30, 2022, 1:00pm - 2:00pmWyss Event
- Add to Calendar
- iCalendar
- Google Calendar
- Outlook
Endothelial cells (ECs) are a heterogeneous and ductile cell type that serves as a critical interface between blood and diverse tissue microenvironments. ECs can adopt brain organotypic properties in response to their interaction a complex ecosystem of cells: adjacent mural smooth muscle cells and pericytes, perivascular immune cells, and surrounding astrocytes that differ across brain... Free and open to public -
Mar 3, 2021, 11:00am - 3:00pmLecture
- Add to Calendar
- iCalendar
- Google Calendar
- Outlook
Biologic drugs comprise 40 percent of the current drug development pipeline. Existing in vitro and animal models are limited in their ability to evaluate the safety and efficacy of these drugs in humans. These limitations often result in development delays and increased costs. Organs-on-chips emulate human biology by providing a micro-engineered environment lined with living... Free and open to public -
Jun 23, 2020, 5:00pm - 6:00pmLecture
- Add to Calendar
- iCalendar
- Google Calendar
- Outlook
Don’t miss these thought-provoking conversations with local leaders in the race to fight COVID-19. Next Tuesday, hear firsthand from Donald E. Ingber, M.D., Ph.D how the Wyss Institute was able to quickly pivot and refocus their unique engineering capabilities on much-needed diagnostic, therapeutic, and vaccine solutions. Free and open to public
Multimedia 46
-
Audio/PodcastAnimal Free Labcast #4 – The PioneerWorld-class pioneer of biomedical research and innovation, Dr. Don Ingber, is the founding director of Harvard University’s Wyss Institute for Biologically Inspired Engineering. In 2010, Dr. Ingber developed a lung-on-a-chip – the first of its kind – and has continued to lead the field by developing numerous other organ chip models, demonstrating their ability to... -
Audio/PodcastPreventing the Next Pandemic with Organ ChipsIn search for strategies to curb pandemics, scientists strive to understand how pathogens slip past the immune system and wreak havoc on the body. To achieve this goal, researchers study viral infection in models that mimic how different cell types interact with each other, the immune system, or the environment. Organ-on-a-chip models combine tissue engineering... -
Audio/PodcastBIOS Podcast – Biologically Inspired Engineering w/ Don Ingber – Founding Director at the Wyss InstituteDon Ingber is the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children’s Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences. He received... -
Video/AnimationWyss Institute Brain Targeting ProgramThis animation explains how Wyss Institute researchers and their industry partners aim to identify novel transport targets and shuttle compounds to enable more effective delivery of drugs to the brain. Credit: Wyss Institute at Harvard University. -
Video/AnimationAdvancing Science and Technology Innovation By Crossing the Art-Science-Design InterfaceWyss Founding Director Donald E. Ingber, M.D., Ph.D., presented on Advancing Science and Technology Innovation by Crossing the Art-Science-Design Interface at the KAUST Circular Carbon Initiative’s 2021 virtual Winter Enrichment Program. Ingber discussed his path from a serendipitous experience in an undergraduate art class that led to his discovery of how living cells are constructed... -
Video/AnimationOMNIVAX: Infection Vaccine PlatformThis video explains how OMNIVAX – an immuno-material-based vaccine technology can be used to rapidly create injectable vaccines against diverse viral and bacterial pathogens, and how the platform is used by the team to develop a vaccine against recurring urinary tract infections (UTIs) in their lead human application. Credit: Wyss Institute at Harvard University.